These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 17097955)

  • 21. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol.
    Radauceanu A; Boivin JM; Bernaud C; Fay R; Zannad F;
    Fundam Clin Pharmacol; 2004 Aug; 18(4):483-91. PubMed ID: 15312156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
    Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
    Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnoea activity in patients with essential hypertension and OSA.
    Heitmann J; Greulich T; Reinke C; Koehler U; Vogelmeier C; Becker HF; Schmidt AC; Canisius S
    Curr Med Res Opin; 2010 Aug; 26(8):1925-32. PubMed ID: 20560730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic efficacy of valsartan and valsartan/HCTZ in mild to moderate hypertensive patients].
    Sun NL; Wang HY; Zhu JR;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Aug; 35(8):715-8. PubMed ID: 17963629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.
    Sugihara M; Miura S; Takamiya Y; Kiya Y; Arimura T; Iwata A; Kawamura A; Nishikawa H; Uehara Y; Saku K
    Hypertens Res; 2009 Jul; 32(7):625-30. PubMed ID: 19461652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study).
    Van der Niepen P; Woestenburg A; Brié H; Vancayzeele S; MacDonald K; Denhaerynck K; Lee C; Hermans C; Abraham I
    Ann Pharmacother; 2009 May; 43(5):849-61. PubMed ID: 19351876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy and safety of the single pill combination of valsartan 80 mg plus amlodipine 5 mg in mild to moderate essential hypertensive patients without adequate blood pressure control by monotherapy].
    Ke YN; Huang J; Zhu JR;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Sep; 37(9):794-9. PubMed ID: 20128376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
    Fogari R; Zoppi A; Derosa G; Mugellini A; Lazzari P; Rinaldi A; Fogari E; Preti P
    J Hum Hypertens; 2007 Mar; 21(3):220-4. PubMed ID: 17215848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
    Düsing R; Handrock R; Klebs S; Tousset E; Vrijens B
    J Hypertens; 2009 Apr; 27(4):894-901. PubMed ID: 19300114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
    Brachmann J; Ansari A; Mahla G; Handrock R; Klebs S
    Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tolerance to valsartan in office practice in 3,197 hypertensive patients (the VALSE study)].
    Ghannad E; Francillon A; Vaillant J; Bourdeix I; Gosse P
    Ann Cardiol Angeiol (Paris); 2000 Feb; 49(1):13-20. PubMed ID: 12555316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study.
    Duprez DA; Florea ND; Jones K; Cohn JN
    J Am Coll Cardiol; 2007 Aug; 50(9):835-9. PubMed ID: 17719468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
    Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
    Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of valsartan and indapamide on plasma cytokines in essential hypertension.
    Xie QY; Wang YJ; Sun ZL; Yang TL
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):629-34. PubMed ID: 17062919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
    White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
    Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.